Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Fortress Biotech reported a quarterly loss of $0.26 per share, significantly better than the Zacks Consensus Estimate of a loss of$ 0.79, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of 67.09% [1] - The company posted revenues of$ 15.12 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 12.58%, and down from $19.95 million in the same quarter last year [2] - Fortress Biotech has surpassed consensus EPS estimates three times over the last four quarters but has not beaten consensus revenue estimates during the same period [2] Stock Performance - Fortress Biotech shares have declined approximately 20.5% since the beginning of the year, compared to a decline of 5.1% for the S&P 500 [3] - The current Zacks Rank for Fortress Biotech is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is$ 1.47 on revenues of $11.84 million, while for the current fiscal year, the estimate is -$ 1.13 on revenues of $155.67 million [7] - The estimate revisions trend for Fortress Biotech is mixed, and changes in these estimates could occur following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]